REGENXBIO partners with Nippon Shinyaku for MPS therapies

REGENXBIO (NASDAQ:RGNX) and Nippon Shinyaku have entered into a partnership for the development and commercialization of REGENXBIO’s gene therapies RGX-121 for the treatment of Hunter syndrome, or MPS II, and RGX-111 for Hurler syndrome, or MPS I.

Under the deal, REGENXBIO (